Literature DB >> 16417952

Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine.

Haitham El Bashir1, Paul T Heath, Thomas Papa, Jens U Ruggeberg, Nik Johnson, Ruchi Sinha, Gail Balfour, Robert Booy.   

Abstract

A randomised, modified, double-blind trial was conducted in children 2 to < 5 years of age to evaluate immunogenicity and reactogenicity of a meningococcal (serogroups A, C, Y, W135) diphtheria toxoid conjugate vaccine (MCV-4) in healthy children previously vaccinated with a monovalent meningococcal C conjugate vaccine. Participants received one dose of either MCV-4 or Haemophilus influenzae type b vaccine (Hib vaccine, control group). Serum bactericidal antibodies (SBA) were determined in sera obtained before and approximately 28 days following vaccination. MCV-4 was highly immunogenic for serogroups A, C, Y and W135, the response to serogroup C being consistent with a booster response in participants primed with monovalent C conjugate vaccine. No major between-group differences in solicited local and systemic reactions or adverse events (AEs).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16417952     DOI: 10.1016/j.vaccine.2005.12.018

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

Review 1.  Emerging vaccines: evidence and considerations for practice integration.

Authors:  Steven M Moss
Journal:  Can Fam Physician       Date:  2007-12       Impact factor: 3.275

2.  Advice for Consideration of Quadrivalent (A, C, Y, W135) Meningococcal Conjugate Vaccine, for use by Provinces and Territories.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2010-01-26

3.  UPDATE ON THE USE OF QUADRIVALENT CONJUGATE MENINGOCOCCAL VACCINES: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors:  This Statement Was Prepared By Dr B Warshawsky
Journal:  Can Commun Dis Rep       Date:  2013-01-02

Review 4.  Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines.

Authors:  David Pace; Andrew J Pollard
Journal:  Arch Dis Child       Date:  2007-10       Impact factor: 3.791

5.  Using the tetravalent meningococcal polysaccharide-protein conjugate vaccine in the prevention of meningococcal disease.

Authors:  Sanford R Kimmel
Journal:  Ther Clin Risk Manag       Date:  2008-08       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.